Intranasal desmopressin (DDAVP, DDVP, Minirin, Stimate Nasal Spray) is no longer indicated for primary nocturnal enuresis and is associated with an increased risk of severe hyponatremia (possibly ...
Nocturia is fairly prevalent. A review by Bosch and Weiss [3] noted that most older men and women experience at least 1 void per night and on average two thirds of patients experience 2 or more voids ...
Please provide your email address to receive an email when new articles are posted on . Desmoda is the first oral solution approved to manage central diabetes insipidus, according to Eton ...
DESMODA is the first and only FDA-approved desmopressin oral solution Commercial launch expected on March 9 th DESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing ...
On Friday, Eton Pharmaceuticals, Inc (NASDAQ:ETON) revealed results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for central ...
DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results